Pharmaceuticals, Biotechnology and Life Sciences
Novartis has reached a delivery milestone of 300 million pediatric antimalarial treatments supplied without profit since 2009, helping to reduce the disease burden for children in more than 30 malaria-endemic countries.
A new, open-source software that can help track the embryonic development and movement of neuronal cells throughout the body of the worm, is now available to scientists.
Johnson & Johnson has completed the acquisition of Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing innovative therapies for curative treatment of chronic hepatitis B virus (HBV) infection.
The FDA has informed that TLipo Escultura Corp. of Brooklyn, NY dba JAT Productos Naturales Corp., and JAT Natural Products…
Eli Lilly and Company will cease development of basal insulin peglispro (BIL), a potential treatment for type 1 and type 2 diabetes, in order to focus research and development efforts on other assets in its portfolio and pipeline.
Genomic Vision – has signed a strategic partnership with the University-Hospital Institute (IHU) Imagine, the largest European genetic research and care cluster.
TxCell SA has signed a 5-year agreement with MaSTherCell, a Contract Manufacturing Organization (CMO), based in Belgium.
According to this agreement, MaSTherCell will be the exclusive manufacturer in Europe of all products from TxCell’s ASTrIA platform.
Sun Pharmaceutical Industries, largest India-based generic pharmaceutical companies, has received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Novartis’ Gleevec.
Anavex has appointed Ulrich Elben, PhD as Vice President of Preclinical Operations, who will be responsible for the pipeline development and optimization.
Premaitha Health said Wednesday that Adgenix has already signed up its first laboratory customer for Premaitha in France, with a signed contract for a minimum of three years to supply LaboSud with the Iona test.